Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Deloitte
Harvard Business School
Dow
Healthtrust
McKesson
Chubb
Johnson and Johnson
Medtronic
Colorcon

Generated: October 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,217,895

« Back to Dashboard

Which drugs does patent 6,217,895 protect, and when does it expire?


Patent 6,217,895 protects ILUVIEN and RETISERT and is included in two NDAs.

This patent has ten patent family members in eight countries.

Summary for Patent: 6,217,895

Title: Method for treating and/or preventing retinal diseases with sustained release corticosteroids
Abstract:The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
Inventor(s): Guo; Hong (Belmont, MA), Ashton; Paul (Boston, MA)
Assignee: Control Delivery Systems (Watertown, MA)
Application Number:09/273,548
Patent Claim Types:
see list of patent claims
Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Alimera Sciences Inc
ILUVIEN
fluocinolone acetonide
IMPLANT;INTRAVITREAL201923-001Sep 26, 2014RXYesYes► Subscribe► SubscribeY TREATMENT OF DIABETIC MACULAR EDEMA
Bausch And Lomb
RETISERT
fluocinolone acetonide
IMPLANT;INTRAVITREAL021737-001Apr 8, 2005RXYesYes► Subscribe► SubscribeY TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,217,895

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,548,078 Method for treating and/or preventing retinal diseases with sustained release corticosteroids► Subscribe
8,252,307Method for treating and/or preventing retinal diseases with sustained release corticosteroids► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,217,895

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia777727► Subscribe
Australia2005200243► Subscribe
European Patent Office1162978► Subscribe
Japan2002539263► Subscribe
South Korea20010112357► Subscribe
MexicoPA01009544► Subscribe
Canada2367092► Subscribe
Brazil0010869► Subscribe
Australia4174800► Subscribe
World Intellectual Property Organization (WIPO)0056340► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Fuji
Cipla
Moodys
Citi
Express Scripts
Teva
US Department of Justice
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot